title: Generic drugs in dermatology: part II.
abstract: In part I, we discussed new drug development, reviewed the history of the generic drug industry, described how generic drugs are approved by the US Food and Drug Administration, and defined the concepts of bioequivalence and therapeutic equivalence. Herein, we explore various factors impacting generic drug use across the different parties involved: the prescriber, the pharmacist, the patient, and the payer. We also include original cost analysis of dermatologic brand name and generic drugs and show the potential cost savings that can be achieved through generic substitution. We conclude with a review of the data addressing potential differences in the effectiveness of brand name versus generic drugs in dermatology. The cost of brand name and generic medications is highly variable by pharmacy, state, and payer. We used one source (www.drugstore.com) as an example and for consistency across all medications discussed herein. Prices included here may not reflect actual retail prices across the United States.
authors.affiliation: Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut 06032, USA. payette@resident.uchc.edu
authors.forename: Michael
authors.initials: M
authors.lastname: Payette
authors.forename: Jane M
authors.initials: JM
authors.lastname: Grant-Kels
mesh_terms: D003879:Dermatologic Agents / Q000191:economics / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D003880:Dermatology / Q000191:economics / Q000639:trends*; D016527:Drug Costs; D016568:Drugs, Generic / Q000191:economics / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D004502:Education, Medical, Continuing; D006801:Humans; D012871:Skin Diseases / Q000188:drug therapy*; D013810:Therapeutic Equivalency; D014481:United States
chemical_list: D003879:Dermatologic Agents; D016568:Drugs, Generic